KRAS and cancer: At present it is in a Phase 1/2 Study to evaluate its safety, tolerability, and clinical activity in patients with cancer having a KRAS G12C mutation (https://clinicaltrials.gov/ct2/show/NCT03785249, accessed on 24 June 2021); and in a Phase 3 clinical trial to compare its efficacy when combined with cetuximab versus chemotherapy in patients with CRC with KRAS G12C mutation (https://www.clinicaltrials.gov/ct2/show/NCT04793958 accessed on 16 July 2021).